Naslov
Autologous Stem Cell Transplantation for Acute Myeloid Leukemia - A 17 Year Single Center Experience

Autori
Sertic, Dubravka ; Nemet, Damir ; Radojčić, Vedran ; Mrsić, Mirando ; Serventi-Seiwerth, Ranka ; Aurer, Igor ; Radman, Ivo ; Zupančić-Šalek, Silva ; Mikulić, Mirta ; Golubić-Čepulić, Branka ; Bojanić, Ines ; Batinić, Drago ; Boban, Ana ; Duraković, Nadira ; Labar, Boris.

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni

Izvornik
Haematologica, Supplement 2 ; Abstract Book of the 10th Congress of the European Hematology Associacion, Stockholm, Sweden / - , 2005

Skup
10th Congress of the European Hematology Associacion

Mjesto i datum
Stockholm, Švedska, 02.06.2005. - 05.06.2005

Vrsta sudjelovanja
Ostalo

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Acute myeloid leukemia; Transplantation

Sažetak
Autologous stem cell transplantation is a standard treatment approach in patient with AML without HLA identical donor younger than 60 year of age. Here we present the results of treatment outcome with autologous transplantation for AML patients in a 17-year period. Patients and methods: From April 1988 to January 2005 142 (69 male and 73 female) patients with AML were treated with intensive therapy followed by reinfusion of autologous stem cell. From December 1996 adult patients with AML in whom CR have been obtained were consecutively submitted to PBSCT. 116 (81, 7%) of them were in first complete remission. The age of transplant recipients was between 2-61 years (median 38 year). The conditioning regimen consisted of busulfan 16 mg/kg BW and cyclophosphamide 120 mg/kg BW ; 18 (12, 68%) patients received fractionated TBI without lung shielding instead of busulfan. 54 pts (38%), received PBSC, 71 pts (50%) BM, and 17 (12%) BM+PBSC. Results: The probability of 5-year overall survival for all patients, irrespectively of their pretransplant disease status (1st CR vs >1st CR) was 45, 6% (1st CR 49, 7%, >1st CR 22, 29% ; p=0, 0002). Disease free survival for the AML patients in 1st CR was 49, 9% and for patients >1st CR 23, 2% (p=0.0002). Relapse rate was significantly lower in patents autografted in 1st CR compared to patients autografted in advanced stage of disease (44, 9% vs. 58, 3%, p=0.0029). There was no difference in OS, DFS, and relapse rate between the patients receiving PBSC or BM. Transplant related mortality was 9.9% for all group. Conclusion: Autologous stem cell transplantation is a standard post- remission treatment for AML patients without HLA identical donor. Relapse rate was significantly lower in patients autografted in 1st CR compared to patients received autologous stem cells in >1st CR.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA